NHS polygenic score debate requires clearer prevention goals, commentary argues

A Nature Medicine commentary examines what responsible consideration of polygenic scores (PGS) within the NHS would require. England’s 10 Year Health Plan commits to establishing a Genomics Population Health Service by 2035, naming PGS as a component technology. The authors also cite the National Cancer Plan’s commitment to personalized risk assessment and a February 2026 PHG Foundation roundtable involving researchers, clinicians, commissioners and ethicists.

The commentary identifies ambiguity about what PGS are intended to achieve. It highlights the prevention paradox: most common disease cases arise in the large population at moderate risk rather than the smaller high-risk group. More accurate risk tools may better define high-risk groups while leaving the moderate-risk majority largely unaddressed. Disagreements over evidence can therefore reflect different priorities for endpoints, comparators and acceptable performance thresholds.

For clinicians and service planners, the argument emphasizes clarifying prevention objectives when assessing risk-stratification tools. This is a commentary, not an evaluation of PGS effectiveness; the supplied subscription preview provides no sample size, quantitative performance estimates or clinical outcome data. The authors declare no competing interests.